Abstract

Spinocerebellar ataxia type 7 (SCA7) is caused by a toxic polyglutamine (polyQ) expansion in the N-terminus of the protein ataxin-7. Ataxin-7 has a known function in the histone acetylase complex, Spt/Ada/Gcn5 acetylase (STAGA) chromatin-remodeling complex. We hypothesized that some histone deacetylase (HDAC) family members would impact the posttranslational modification of normal and expanded ataxin-7 and possibly modulate ataxin-7 function or neurotoxicity associated with the polyQ expansion. Interestingly, when we coexpressed each HDAC family member in the presence of ataxin-7 we found that HDAC3 increased the posttranslational modification of normal and expanded ataxin-7. Specifically, HDAC3 stabilized ataxin-7 and increased modification of the protein. Further, HDAC3 physically interacts with ataxin-7. The physical interaction of HDAC3 with normal and polyQ-expanded ataxin-7 affects the toxicity in a polyQ-dependent manner. We detect robust HDAC3 expression in neurons and glia in the cerebellum and an increase in the levels of HDAC3 in SCA7 mice. Consistent with this we found altered lysine acetylation levels and deacetylase activity in the brains of SCA7 transgenic mice. This study implicates HDAC3 and ataxin-7 interaction as a target for therapeutic intervention in SCA7, adding to a growing list of neurodegenerative diseases that may be treated by HDAC inhibitors.

Highlights

  • Spinocerebellar ataxia type 7 (SCA7) is a rare neurodegenerative disease caused by a trinucleotide repeat expansion in the ataxin-7 gene [1,2,3]

  • Many polyglutamine diseases, including SCA7, feature transcriptional deregulation associated with altered acetylation state [17,34,35] and cellular toxicity that is reversible by histone deacetylase (HDAC) inhibition [35]

  • In this study we focused on a role for HDAC family members in ataxin-7 regulation

Read more

Summary

Introduction

Spinocerebellar ataxia type 7 (SCA7) is a rare neurodegenerative disease caused by a trinucleotide repeat expansion in the ataxin-7 gene [1,2,3]. SCA7 is one of nine known polyglutamine (polyQ) diseases characterized by aggregation of polyQ-expanded protein, nuclear inclusions and repeat-dependent neuronal toxicity [4,5]. In SCA7 patients there is increased localization of ataxin-7 to discrete nuclear inclusions [6,7,11,12]. Aggregation of polyglutamine-expanded ataxin-7 into the nucleus, concomitant with neurodegeneration and transcriptional deregulation, is a feature of SCA7 transgenic mouse models [13,14,15,16]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.